Search Results

To address this, we developed the NTF release sensor (NRS), a genetically encoded reporter that facilitates latrophilin-type aGPCR Cirl/ADGRL in Drosophila, revealing NTF release and receptor dissociation within the developing Tobias Langenhan's group, where I currently manage a project to establish a drug screening assay for In addition, the platform was used to develop assays for high-throughput screening for challenging adhesion research aims to leverage this knowledge to identify novel pharmacological targets and contribute to the development

- Quantifying agonist pharmacology and biased agonism Class 3 - Antagonist pharmacology and binding assay the Optimization of Candidate Selection Lecture 1: The Eyes to See- The Importance of Pharmacologic Assays Aside from his vast experience in drug development, not to mention his extensive publication record,

He is the Research director at INSERM with a specific interest in G protein-coupled receptors by developing original BRET and TR-FRET assays. loss-of-function variants of the MT2 melatonin receptors that are associated with type 2 diabetes (TD2) development

He is passionate about developing more rational ways to understand and engineer biology. technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays

drug discovery with predictive molecular modeling that forecasts receptor behavior—before the first assay receptor-ligand interactions after the fact; they aim to forecast receptor behavior before the first assay affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the first adenosine receptor binding assay.

pharmacological chaperones, his work on bioluminescence resonance energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug discovery.

Prioritize assays based on project phase and decision points Map go/no-go logic that guides program momentum they’ll change outcomes No More Strategy Swirl I build structure that sticks—from CRO engagement to assay

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights

pharmacological chaperones, his work on bioluminescence resonance energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug discovery. a member of the lab, I am humbled to have been able to work with him and his team and use the tools developed

clear expectations and deliverables to build trust and reduce delays • Align teams across roles—from assay Decisions—Not Delays I help turn great science into clear deliverables • Define program objectives and guide assay

To stay relevant in the next decade, it’s not about chasing the latest assay or tool.

- Quantifying agonist pharmacology and biased agonism Class 3 - Antagonist pharmacology and binding assay the Optimization of Candidate Selection Lecture 1: The Eyes to See- The Importance of Pharmacologic Assays Aside from his vast experience in drug development, not to mention his extensive publication record, Summit A global gathering of researchers and professionals showcasing the latest developments in GPCR

His journey highlights the transition from general drug development to a deep dive into G protein-coupled Despite the availability of modern tools, Ben stresses the enduring value of classical methods like GTPγS assays mentorship, open communication, and peer learning — especially from undergraduate trainees — shape his development Using site-directed mutagenesis and pharmacological synergy assays , his team aims to understand how Clements' work is primarily focused on translational developments of small molecule therapeutics, and

Yamina will continue to develop and manage the Dr. Badr recounted Badr's Journey, Multiplexing Assays, and Collaboration Badr shared his learning process Yamina emphasized the potential of multiplexing assays in expanding the scope of scientific exploration understanding how Badr’s experiences influenced his current role, and Badr stressed the need for individuals to develop

I employ a multidisciplinary approach that combines molecular pharmacology, biochemical assays, and biophysical GPCR Title: Development of a Transgenic Mouse Platform for the Detection of Endogenous G protein Activity

Eric Trinquet —how structured play turns into assays and why serendipity belongs in your build process affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

I study the cell and tissue level consequences of its failure in foetal development and of its reemployment were born at predicted Mendelian frequencies, appeared grossly indistinguishable from Con mice, and developed Since staring my postdoctoral training, I have continued to develop my expertise to answer fundamental and gene expression assays. Ligand-induced GPR110 signaling stimulates neurogenesis and synaptogenesis during development, and the

She developed expertise over the past two decades studying structure/function relationships of GPCRs Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors Driven by a passion for advancing drug development, John is committed to leveraging his expertise to research focuses on elucidating the molecular basis of membrane protein signalling using quantitative assays Further down the track, he aims to apply this knowledge to develop novel chemical treatments for neuronal

This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor GPCR Podcast Read full article Back when GPCR assays were performed with single channel pipettes, failure Michelle Halls still remembers pipetting one sample at a time, holding her breath to keep the assay alive To stay relevant in the next decade, it’s not about chasing the latest assay or tool. Get it wrong, and the best molecule on paper stalls in development.

This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

the Forefront of GPCR Drug Discovery Gain insider methods from the pioneers shaping biased signaling, assay Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies for assay Weekly GPCR Insights (papers, jobs, events) Networking with a global scientist community One failed assay Aside from his vast experience in drug development, not to mention his extensive publication record, We have a 90% discount for people who live and work in developing countries and a 15% discount for team

In this AMA session, you’ll learn how to: Decode GPCR signaling complexity using functional assay strategies affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

Work from our lab showed that the PCP components, including ADGRC2 and ADGRC3, are localized in the developing My research focus is the mechanisms of neural circuit development, function and disease." To exploit this expression profile, we have developed antibody-drug conjugates (ADCs) targeting CD97, We initially tested the ADC using in vitro WST-8 viability assays in human GBM cell lines and cell types oncogenesis in glioblastoma, the most common brain malignancy, and chromatin organization in human neural development

, to exploit a Ric-8-based technology to purify recombinant G proteins and to use the G proteins in assays

They also discussed the ongoing developments in the GPCR field, the upcoming adhesion GPCR consortium He explained that initially, the field lacked adequate tools, and his lab had to develop new techniques their understanding of the GPCRs through various approaches, including structural biology and signaling assays Yamina expressed her appreciation for Demet's work and asked about the development of the GPCR field GPCR Field and Naming Convention Discussion Demet and Yamina discussed the ongoing developments in the

Translate project strategy into clear decision-driving assays Eliminate “nice to have” tests that stall

To further develop these ideas, I joined the lab of Dr. John's Chemistry Olympiad Journey John shared his experiences in high school, where he developed a keen working on a project involving receptor kinases and collaborating with other postdocs in the lab to develop assays and improve the biochemistry of certain targets. John suggested starting preparations a year to two years ahead due to the time needed to develop ideas

David Tuveson at CSHL where he participated in the development of an organoid system for the culture normal and malignant pancreatic tissue, allowing advances in sequencing, target discovery and biomarker development He also continued his interest in computational analysis of cancer drivers by co-developing GECCO, an Mike shared his strategy of developing preliminary projects and gathering data to strengthen his application exploration of dosage and length of treatment in a mouse model and suggested using a biosensor-based assay

High throughput GPCR screening technologies enable deciphering host-microbiome communication and the development 12 2022 12:40:00 GMT+0000 (Coordinated Universal Time) Details Getting the most from your biosensor assays